Minnesota Administrative Rules

9810.2502 MEDICAL CANNABIS RETAIL.

Subpart 1.

Applicability.

This part applies to retail sales of all medical cannabis flower, medical cannabinoid products, and other regulated products sold by a medical cannabis retailer.

Subp. 2.

Identity verification.

Before distributing medical cannabis flower or medical cannabinoid products, a medical cannabis retailer must verify the identity of the recipient and, if applicable, the associated patient's enrollment in the registry. A patient or caregiver must provide the medical cannabis retailer with:

A.

the patient's or caregiver's valid government-issued photo identification; and

B.

the patient's medical cannabis program verification document or registry number or other proof that the patient is actively enrolled in the registry.

Subp. 3.

Patient self-evaluation.

During the first year of enrollment, a patient must complete a patient self-evaluation when first purchasing medical cannabis flower or medical cannabinoid products and every three months thereafter. A medical cannabis retailer must only distribute medical cannabis flower or medical cannabinoid products to a patient with an up-to-date self-evaluation in the registry, as applicable. A patient may complete the patient's self-evaluation on-site before receiving medical cannabis flower or medical cannabinoid products.

Subp. 4.

Patient self-evaluation; verification.

Before distributing medical cannabis to a patient or caregiver, a medical cannabis retailer must verify that the patient has completed a self-evaluation as required under subpart 3. If a self-evaluation is required and the patient has not completed the self-evaluation, a medical cannabis retailer must assist the patient in completing the self-evaluation.

Subp. 5.

Patient consultation.

A licensed pharmacist or certified medical cannabis consultant must be available to provide a consultation to the patient or caregiver to determine the proper medical cannabis flower or medical cannabinoid product, recommended dosage, and paraphernalia for the patient if required under Minnesota Statutes, section 342.51, subdivision 3, paragraph (a). A patient consultation must include:

A.

review of patient information in the registry;

B.

review of the range of chemical compositions of medical cannabis flower or medical cannabinoid products intended for distribution;

C.

an assessment of the perceived effectiveness of the medical cannabis flower or medical cannabinoid product intended for purchase at treating the condition or symptoms of the condition; and

D.

as applicable, any relevant information on the use of medical cannabis paraphernalia.

Subp. 6.

Patient-specific labeling.

Before distributing medical cannabis flower and medical cannabinoid products to a patient or caregiver, a pharmacist or certified medical cannabis consultant must apply a patient-specific label to the medical cannabis flower and medical cannabinoid products in accordance with part 9810.1402.

Statutory Authority:

MS s 342.02

History:

49 SR 1143

Published Electronically:

April 25, 2025